Current Research Studies
Cancer - ANBL1232: Utilizing Response - and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma - a Groupwide Historically Controlled Phase 3 Study
Condition or Therapy:
Cancer and Blood Disorders
Study Number: ANBL1232
What is the goal of this study?
The goal of this study is to use response- and biology-based, risk-guided therapy in treating patients with non-high-risk neuroblastoma instead of using standard treatment.
Who can join the study?
This study may be a good fit for children who:
- are up to 18 months old, and
- have been newly diagnosed with v-myc avian myelocytomatosis viroal oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma (International Classification of Diseases for Oncology morphology 9500/3) or MYCN non-amplified ganglioneuroblastoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.